Keros Therapeutics, Inc. (KROS) shares ended the last trading session 9.8% higher at $15.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
20/10 Keros Therapeutics lance une offre publique de rachat d'actions pouvant atteindre 194,4 millions de dollars MT 20/10 Keros Therapeutics lance un programme de rachat d'actions portant sur 35,94% ...
In other recent news, Keros Therapeutics, Inc. has announced agreements to repurchase shares from ADAR1 Capital Management and Pontifax Venture Capital for a total of approximately $181 million. This ...
Keros, a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to transforming growth factor-beta protein signaling, stated it continues to target a first ...
While not a mind-blowing move, it is good to see that the Keros Therapeutics, Inc. (NASDAQ:KROS) share price has gained 12% in the last three months. But that isn't much consolation for the painful ...
Ces derniers mois, plusieurs projets fabriqués avec de l’intelligence artificielle ont été publiés sur les profils de plateformes de streaming d’artistes bien réels, à leur insu. A qui profite le ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Keros Therapeutics ( (KROS)) has provided ...
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...
Keros Therapeutics has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy (DMD ...
Fintel reports that on June 10, 2025, B of A Securities downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Buy to Neutral. Analyst Price Forecast Suggests 89.41% Upside As of June 2, ...
Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback